Efficacy of Arbidol in treatment of COVID-19

Phase 2

Recruiting

• Conditions: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).; U07.1; COVID-19, virus identified

• Registration Number: IRCT20201024049134N1
• Lead Sponsor: Babol University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

People over the age of 65 who are in high-risk groups (with a history of high blood pressure, diabetes, BMI> 30, COPD, cancer, and etc.)
Confirmation of the diagnosis of COVID-19 by chest CT scan and/or rt-PCR
Signing an informed consent form

Exclusion Criteria

History of allergies to these drugs
Use arbidol before hospitalization
Pregnant women
Respiratory failure and need for mechanical ventilation
Renal and/or hepatic failure
Anemia and thrombocytopenia
Coagulopathy
Autoimmune or immune deficiency disorders

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time of the removal of the symptoms. Timepoint: Up to 1 month after the end of the study. Method of measurement: Examination of the patients by infectious disease specialists in an outpatient clinic.;Hospitalization required. Timepoint: Up to 1 month after the end of the study. Method of measurement: Examination of the patients by infectious disease specialists in an outpatient clinic.;Life-threatening conditions. Timepoint: Up to 1 month after the end of the study. Method of measurement: Examination of the patients by infectious disease specialists in an outpatient clinic.;Death. Timepoint: Up to 1 month after the end of the study. Method of measurement: Examination of the patients by infectious disease specialists in an outpatient clinic.